Quanterix Corporation’s commercial brand, Lucent Diagnostics, announced a partnership with Life Line Screening on March 2 2026 that will allow the company’s non‑invasive blood‑based biomarker test to be offered across Life Line’s national network. Initial programs are already underway in Florida, California and Texas, and the partnership will enable testing to be performed at community centers, churches and senior centers, with results shared with primary‑care physicians to support early intervention for adults at risk of Alzheimer’s disease and mild cognitive impairment.
The collaboration leverages Life Line Screening’s mobile delivery model to bring Lucent’s ultra‑sensitive Simoa technology into community settings, a key step toward democratizing access to Alzheimer’s diagnostics. By expanding into non‑clinical environments, Quanterix can reach a broader segment of the population, potentially accelerating adoption of its blood‑test and increasing market penetration in a rapidly growing diagnostic space.
Management emphasized the strategic importance of the partnership. "Scientific rigor shouldn’t stop at the laboratory door. Through LLS, Lucent Diagnostics is bringing validated, high‑quality science into community testing networks, helping ensure that everyone has access to information for use by their physician and not only in a research setting. This is a critical step toward earlier, more reliable detection of Alzheimer’s Disease," said Lucent Diagnostics General Manager Zachary Fernandes. Jim Waters, Chief Operating Officer of Life Line Screening, added, "Too many chronic conditions go undetected until they become life‑altering events. By partnering with Lucent Diagnostics, we’re able to continue to expand our mission of uncovering asymptomatic risks earlier and more equitably. This partnership has the potential to impact numerous lives by supporting more informed treatment pathways, and it’s something we’re excited to bring to communities across the country."
The partnership aligns with Quanterix’s broader strategy to broaden the reach of its Simoa‑based diagnostics and to capture a larger share of the Alzheimer’s blood‑testing market. By embedding its technology into community screening programs, Quanterix positions itself to benefit from the growing demand for early, non‑invasive diagnostic tools, while Life Line Screening expands its service portfolio and reinforces its commitment to early detection of chronic conditions.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.